Monoclonal antibodies and progressive multifocal leukoencephalopathy

References

• Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958; 81:93 - 111
   PubMed Web of Science ®Google Scholar
• ZuRhein G, Chou S. Particles resembling papovavirions in human cerebral demyelinating disease. Science 1965; 148:1477 - 1479
   PubMed Web of Science ®Google Scholar
• Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1:1257 - 1260
   PubMed Web of Science ®Google Scholar
• Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84:1499 - 1504
   PubMed Web of Science ®Google Scholar
• Walker D, Padgett B. Sever J, Madden D. The epidemiology of human polyomaviruses. Polyomaviruses and human neurological disease 1983; New York Alan R. Liss, Inc 99 - 106
   Google Scholar
• Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 1999; 52:253 - 260
   PubMed Web of Science ®Google Scholar
• Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H. JC virus detection in bodily fluids: Clues to transmission. Clin Infect Dis 2006; 43:9 - 12
   PubMed Web of Science ®Google Scholar
• Chang H, Wang M, Tsai RT, Lin HS, Huan JS, Wang WC, et al. High incidence of JC viruria in JC-seropositive older individuals. J Neurovirol 2002; 8:447 - 451
   PubMed Web of Science ®Google Scholar
• Bofill-Mas S, Girones R. Excretion and transmission of JCV in human populations. J Neurovirol 2001; 7:345 - 349
   PubMed Web of Science ®Google Scholar
• Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984; 2:299 - 313
   PubMed Web of Science ®Google Scholar
• Bernick C, Gregorios JB. Progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome. Arch Neurol 1984; 41:780 - 782
   PubMed Web of Science ®Google Scholar
• Miller JR, Barrett RE, Britton CB, Tapper ML, Bahr GS, Bruno PJ, et al. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982; 307:1436 - 1438
   PubMed Web of Science ®Google Scholar
• Snider WD, Simpson DM, Nielsen S, Gold JW, Metroka CE, Posner JB. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol 1983; 14:403 - 418
   PubMed Web of Science ®Google Scholar
• Gillespie SM, Chang Y, Lemp G, Arthur R, Buchbinder S, Steimle A, et al. Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981–1989. Ann Neurol 1991; 30:597 - 604
   PubMed Web of Science ®Google Scholar
• Holman RC, Torok TJ, Belay ED, Janssen RS, Schonberger LB. Progressive multifocal leukoencephalopathy in the United States, 1979–1994: increased mortality associated with HIV infection. Neuroepidemiology 1998; 17:303 - 309
   PubMed Web of Science ®Google Scholar
• Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987; 107:78 - 87
   PubMed Web of Science ®Google Scholar
• Kure K, Llena JF, Lyman WD, Soeiro R, Weidenheim KM, Hirano A, et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol 1991; 22:700 - 710
   PubMed Web of Science ®Google Scholar
• Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997; 176:632 - 636
   PubMed Web of Science ®Google Scholar
• Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009; 48:1459 - 1466
   PubMed Web of Science ®Google Scholar
• Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 2001; 56:257 - 260
   PubMed Web of Science ®Google Scholar
• Gray F, Chretien F, Vallat-Decouvelaere AV, Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003; 62:429 - 440
   PubMed Web of Science ®Google Scholar
• Yoritaka A, Ohta K, Kishida S. Prevalence of neurological complications in Japanese patients with AIDS after the introduction of HAART. Rinsho Shinkeigaku 2007; 47:491 - 496
   PubMedGoogle Scholar
• Collazos J. Opportunistic infections of the CNS in patients with AIDS: diagnosis and management. CNS Drugs 2003; 17:869 - 887
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369 - 374
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375 - 381
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362 - 368
   PubMed Web of Science ®Google Scholar
• Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences. N Engl J Med 2005; 353:414 - 416
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924 - 933
   PubMed Web of Science ®Google Scholar
• Tysabri Update 2009; (Accessed 2009; at http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTAwODZ8Q2 hpbGRJRD0tMXxUeXBlPTM=&t = 1).
   Google Scholar
• Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004; 22:427 - 435
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073 - 3080
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004 - 2013
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834 - 4840
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676 - 688
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270 - 1272
   PubMed Web of Science ®Google Scholar
• Garcia-Suarez J, de Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80:271 - 281
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 2008; 8:144 - 146
   PubMed Web of Science ®Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003; 9:38 - 41
   PubMed Web of Science ®Google Scholar
• Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, Mediati M, Losciale L, Nebuloni M, et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol 1999; 5:125 - 133
   PubMed Web of Science ®Google Scholar
• Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318:301 - 305
   PubMed Web of Science ®Google Scholar
• Major EO, Amemiya K, Elder G, Houff SA. Glial cells of the human developing brain and B-cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus JCV. J Neurosci Res 1990; 27:461 - 471
   PubMed Web of Science ®Google Scholar
• Atwood W, Amemiya K, Traub R, Harms J, Major E. Interactions of the human polyomavirus, JCV, with human B lymphocytes. Virology 1992; 190:716 - 723
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996; 70:7004 - 7012
   PubMed Web of Science ®Google Scholar
• Houff SA, Berger JR. The bone marrow, B-cells and JC virus. J Neurovirol 2008; 14:341 - 343
   PubMed Web of Science ®Google Scholar
• Marzocchetti A, Wuthrich C, Tan CS, Tompkins T, Bernal-Cano F, Bhargava P, et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 2008; 14:455 - 458
   PubMed Web of Science ®Google Scholar
• Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet 2009; 5:1000368
   PubMed Web of Science ®Google Scholar
• Weber T, Weber F, Petry H, Luke W. Immune response in progressive multifocal leukoencephalopathy: an overview. J Neurovirol 2001; 7:311 - 317
   PubMed Web of Science ®Google Scholar
• Berger JR, Scott G, Albrecht J, Belman AL, Tornatore C, Major EO. Progressive multifocal leukoencephalopathy in HIV-1-infected children. Aids 1992; 6:837 - 841
   PubMed Web of Science ®Google Scholar
• Andréoletti L, Lescieux A, Lambert V, Si-Mohamed A, Matta M, Wattré P, et al. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol 2002; 66:1 - 7
   PubMed Web of Science ®Google Scholar
• Tornatore C, Berger J, Winfield D, LaVoie L, Major E. Detection of JC viral genome in the lymphocytes of non-PML HIV positive patients: association with B-cell lymphopenia. Neurology 1992; 42:211
   Google Scholar
• Fedele CG, Ciardi MR, Delia S, Contreras G, Perez JL, De Oña M, et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9:551 - 558
   PubMed Web of Science ®Google Scholar
• Andréoletti L, Dubois V, Lescieux A, Dewilde A, Bocket L, Fleury HJ, et al. Human polyomavirus JC latency and reactivation status in blood of HIV-1-positive immunocompromised patients with and without progressive multifocal leukoencephalopathy. Aids 1999; 13:1469 - 1475
   PubMed Web of Science ®Google Scholar
• Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4:59 - 68
   PubMed Web of Science ®Google Scholar
• Berenguer J, Miralles P, Arrizabalaga J, Ribera E, Dronda F, Baraia-Etxaburu J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36:1047 - 1052
   PubMed Web of Science ®Google Scholar
• Berger JR, Tornatore C, Major EO, Bruce J, Shapshak P, Yoshioka M, et al. Relapsing and remitting human immunodeficiency virus-associated leukoencephalomyelopathy. Ann Neurol 1992; 31:34 - 38
   PubMed Web of Science ®Google Scholar
• Du Pasquier RA, Clark KW, Smith PS, Joseph JT, Mazullo JM, De Girolami U, et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:318 - 322
   PubMed Web of Science ®Google Scholar
• Du Pasquier RA, Kuroda MJ, Zheng Y, Jean-Jacques J, Letvin NL, Koralnik IJ. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127:1970 - 1978
   PubMed Web of Science ®Google Scholar
• Cinque P, Pierotti C, Viganò MG, Bestetti A, Fausti C, Bertelli D, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:358 - 363
   PubMed Web of Science ®Google Scholar
• Evans AS. Hypothesis: the pathogenesis of AIDS. Activation of the T- and B-cell cascades. Yale J Biol Med 1984; 57:317 - 327
   PubMed Web of Science ®Google Scholar
• Epeldegui M, Widney DP, Martinez-Maza O. Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B-cell activation-associated molecular lesions. Curr Opin Oncol 2006; 18:444 - 448
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B-cells in multiple sclerosis. Neurology 2008; 71:1350 - 1354
   PubMed Web of Science ®Google Scholar
• Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194:153 - 164
   PubMed Web of Science ®Google Scholar
• Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE 2008; 3:2028
   Web of Science ®Google Scholar
• Du Pasquier RA, Schmitz JE, Jean-Jacques J, Zheng Y, Gordon J, Khalili K, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004; 78:10206 - 10210
   PubMed Web of Science ®Google Scholar
• Marzocchetti A, Lima M, Tompkins T, Kavanagh DG, Gandhi RT, O'Neill DW, et al. Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. Virology 2009; 383:173 - 177
   PubMed Web of Science ®Google Scholar
• del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T-cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65:1596 - 1603
   PubMed Web of Science ®Google Scholar
• Ko HH, Bressler B. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. Expert Rev Gastroenterol Hepatol 2007; 1:29 - 39
   PubMedGoogle Scholar
• Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208:297 - 306
   PubMed Web of Science ®Google Scholar
• Papp KA. Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator. Drugs Today (Barc) 2004; 40:889 - 899
   PubMed Web of Science ®Google Scholar
• Capsoni F, Ongari AM, Frigerio E, Taglioni M, Altomare GF. Effect of Efalizumab on neutrophil and monocyte functions in patients with psoriasis. Int J Immunopathol Pharmacol 2008; 21:437 - 445
   PubMed Web of Science ®Google Scholar
• Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, et al. Increase in TNFalpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102:19057 - 19062
   PubMed Web of Science ®Google Scholar
• Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006; 12:171 - 178
   PubMed Web of Science ®Google Scholar
• Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B-cell reconstitution after rituximab treatment of lymphoma recapitulates B-cell ontogeny. Clin Immunol 2007; 122:139 - 145
   PubMed Web of Science ®Google Scholar
• Corti P, Peters C, Balduzzi A, Bertagnolio B, Biondi A, Bugarin C, et al. Reconstitution of lymphocyte subpopulations in children with inherited metabolic storage diseases after haematopoietic cell transplantation. Br J Haematol 2005; 130:249 - 255
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B-cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:613 - 620
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B-cells and T-cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63 - 70
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T-cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22:185 - 191
   PubMed Web of Science ®Google Scholar
• Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36:755 - 768
   PubMed Web of Science ®Google Scholar
• Jones JL, Coles AJ. Campath-1H treatment of multiple sclerosis. Neurodegener Dis 2008; 5:27 - 31
   PubMed Web of Science ®Google Scholar
• Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004; 106:270 - 274
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43:16 - 24
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110:2316 - 2323
   PubMed Web of Science ®Google Scholar
• Waggoner J, Martinu T, Palmer SM. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 2009; 28:395 - 398
   PubMed Web of Science ®Google Scholar
• Ravandi F, O'Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24:718 - 725
   PubMed Web of Science ®Google Scholar
• Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J Neurovirol 2001; 7:280 - 287
   PubMed Web of Science ®Google Scholar